research Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report
A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
Search
for
Sort by
Research
210-240 / 414 results 
research Peripheral Neuropathy Associated with Tofacitinib Use in Alopecia Universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Consensus on the Treatment of Alopecia Areata – Brazilian Society of Dermatology
Tailored treatments for alopecia areata are recommended based on severity and patient needs.
research Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research The Frontal Fibrosing Alopecia Treatment Dilemma
Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
research An Update in the Management of Alopecia Areata
New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
research The Pattern and Clinical Profile of Alopecia Areata: Panoramic Review, Update, and Advances on Etiopathogenesis, Associated Factors, Diagnosis, Complications, Management, and Prognosis in Treatment 2023
Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.
research Androgenetic Alopecia – Update 2022
research The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19
Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Alopecia Areata in Latin America: Where Are We and Where Are We Going?
Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
research Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Tofacitinib Citrate Alleviates Alopecia Universalis Symptoms in Recent Case Study
Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
research Alopecia Universalis Unresponsive to Treatment with Tofacitinib: Report of a Case with a Brief Review of the Literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Recalcitrant Alopecia Areata Responsive to Leflunomide and Anthralin—Potentially Undiscovered JAK/STAT Inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Alopecia Areata Triggered by Psychological Stress and Successfully Treated with a Janus Kinase Inhibitor: Case Report
Stress-related hair loss was reversed with a special medication.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Alopecia Areata: Genetic and Immunological Insights
Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.